Fernandez-Julian E, et al. - Researchers probed into the outcomes including efficacy, quality of life, and levels of inflammatory markers of a mandibular advancement device (MAD) for moderate-to-severe obstructive sleep apnea (OSA). This device led to substantial improvement in the polysomnographic parameters, quality of life, and some inflammatory markers (C-reactive protein (CRP), interleukin (IL)-β, and tumor necrosis factor (TNF)-α) in a major proportion of patients with moderate OSA and in some patients with severe OSA. Therefore, MAD could serve as a viable alternative therapy in patients with moderate-to-severe OSA who refuse continuous positive airway pressure.